Quality evidence is needed to support a new Medicare Part D medication therapy management (MTM) program performance measure, prompting a scoping review on MTM services and associated outcomes.
Corporate climate credibility increasingly hinges on Scope 3 emissions, and yet individual companies have the least direct control over these emissions. Meeting ambitious Scope 3 targets requires ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results